본문 바로가기
KERD
논문KCI 등재

Species Distribution and Susceptibility to Azole Antifungals of Candida Bloodstream Isolates from Eight University Hospitals in Korea

신명근|김수현|이경원|김미나|장철훈|이혜수|어영|신보문|양동욱|신종희|이위교|서순팔|이진솔
연세대학교의과대학 (Yonsei University College of Medicine)|2007.10|Yonsei Medical Journal|제48권 제5호|pp. 779-786

2

조회

0

다운로드

21

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Purpose: The incidence of Candida bloodstream infections (BSI) has increased over the past two decades. The rank order of occurrence and the susceptibility to antifungals of the various Candida species causing BSI are important factors driving the establishment of empirical treatment protocols; however, very limited multi-institutional data are available on Candida bloodstream isolates in Korea. Materials and Methods: We investigated the susceptibility to azole antifungals and species distribution of 143 Candida bloodstream isolates recovered from eight university hospitals over a six-month period. Minimal inhibitory concentrations (MICs) of fluconazole, itraconazole, and voriconazole for each isolate were determined by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI). Results: The Candida species recovered most frequently from the blood cultures was C. albicans (49%), followed by C. parapsilosis (22%), C. tropicalis (14%), and C. glabrata (11%). The MIC ranges for the Candida isolates were 0.125 to 64μg/mL for fluconazole, 0.03 to 2μg/mL for itraconazole, and 0.03 to 1μg/mL for voriconazole. Overall, resistance to fluconazole was found in only 2% of the Candida isolates (3/143), while the dose- dependent susceptibility was found in 6% (8/143). The resistance and dose-dependent susceptibility of itraconazole were found in 4% (6/143) and 14% (20/143) of the isolates, respectively. All bloodstream isolates were susceptible to voriconazole (MIC,≤1μg/mL). Conclusion: Our findings show that C. albicans is the most common cause of Candida-related BSI, followed by C. parapsilosis, and that the rates of resistance to azole antifungals are still low among bloodstream isolates in Korea.

참고문헌 (36)

  1. Edmond MB, "Nosocomial bloodstream infections in United States hospitals:a three-year analysis", 29, pp.239~244 (1999)
  2. Shin JH, "Genetic relatedness among Candida tropicalis isolates from sporadic cases of fungemia in two university hospitals in Korea", 25, pp.634~640 (2004)
  3. Verduyn Lunel FM, "Nosocomial fungal infections:candidemia", 34, pp.213~220 (1999)
  4. Kao AS, "The epidemiology of candidemia in two United States cities:results of a population-based active surveillance", 29, pp.1164~1170 (1999)
  5. Pfaller MA, "International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program", 39, pp.3254~3259 (2001)
  6. Hospenthal DR, "The role of antifungal susceptibility testing in the therapy of candidiasis", 48, pp.153~160 (2004)
  7. Pfaller MA, "Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998", 44, pp.747~751 (2000)
  8. St Germain G, "Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada", 39, pp.949~953 (2001)
  9. Cuenca-Estrella M, "In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003", 55, pp.194~199 (2005)
  10. Samra Z, "Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel", 24, pp.592~595 (2005)
  11. da Matta DA, "Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in So Paulo, Brazil, 1995-2003", 18, pp.399~404 (2007)
  12. Mokaddas EM, "Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study", 56, pp.255~259 (2007)
  13. Lee K, "High prevalence of ceftazidime- resistant Klebsiella pneumoniae and increase of imipenem- resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004", 47, pp.634~645 (2006)
  14. Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved standard M27-A2" (2002), PA: Clinical and Laboratory Standards Institute
  15. Yi JY, "Evaluation of spectrophotometric broth microdilution method to determine the fluconazole MIC of the Candida Species", 22, pp.253~259 (2002)
  16. Arthington-Skaggs BA, "Quantitation of ergosterol content:novel method for determination of fluconazole susceptibility of Candida albicans", 37, pp.3332~3337 (1999)
  17. Pfaller MA, "Correlation of MIC with outcome for Candida species tested against voriconazole:analysis and proposal for interpretive breakpoints", 44, pp.819~826 (2006)
  18. Rex JH, "Practice guidelines for the treatment of candidiasis", 30, pp.662~678 (2000)
  19. Voss A, "Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals", 15, pp.909~912 (1996)
  20. Abi-Said D, "The epidemiology of hematogenous candidiasis caused by different Candida species", 24, pp.1122~1128 (1997)
  21. Pfaller MA, "International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida", 10, pp.11~23 (2004)
  22. Krcmry V Jr, "Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group", 36, pp.7~11 (2000)
  23. Takakura S, "National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin", 53, pp.283~289 (2004)
  24. Collin B, "Antifungal resistance in non-albicans Candida species", 2, pp.9~14 (1999)
  25. Pfaller MA, "International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group", 36, pp.1886~1889 (1998)
  26. Shin JH, "Electrophoretic karyotype analysis of sequential Candida parapsilosis isolates from patients with persistent or recurrent fungemia", 39, pp.1258~1263 (2001)
  27. Shin JH, "Biofilm production by isolates of Candida species recovered from nonneutropenic patients:comparison of bloodstream isolates with isolates from other sources", 40, pp.1244~1248 (2002)
  28. Levin AS, "Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers", 30, pp.243~249 (1998)
  29. Pfaller MA, "National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic", 30, pp.121~129 (1998)
  30. Pappas, "A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and paediatric patients", 37, pp.634~643 (2003)
  31. Sanguinetti M, "Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance", 49, pp.668~679 (2005)
  32. Hajjeh RA, "Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program", 42, pp.1519~1527 (2004)
  33. Pfaller MA, "In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp", 46, pp.1723~1727 (2002)
  34. Tortorano AM, "The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood", 52, pp.679~682 (2003)
  35. Rex JH, "Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards", 24, pp.235~247 (1997)
  36. Rex JH, "Resistance of Candida species to fluconazole", 39, pp.1~8 (1995)

관련 논문AI추천

Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea김수현, 박연준, 신종희, 이경원, 이위교, 정숙인, 주민영, 최현정대한진단검사의학회 · Annals of Laboratory Medicine2012 · 제32권 제6호In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values김미나, 김수현, 서순팔, 송은송, 신명근, 신종희, 양동욱, 이경원, 이미경, 이위교, 이혜수, 장민중, 장철훈, 장희창대한진단검사의학회 · Annals of Laboratory Medicine2013 · 제33권 제3호First Case of Echinocandin-Resistant Candida albicans in Korea강철인, 박민승, 박종은, 송동준, 신종희, 이남용, 허희재, 박실비아대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제6호A Multicenter Study of Antifungal Use and Species Distribution and Antifungal Susceptibilities of Candida Isolates in South Korea김수현, 김영아, 신경섭, 신정환, 신종희, 신주현, 원은정, 이다인, 이동현, 이종윤, 정석훈대한의진균학회 · 대한의진균학회지2020 · 제25권 제1호CLSI 액체배지 미량희석법, Etest 및 Minimum Fungicidal Concentration 검사에 의한 국내 혈액에서 분리된 효모균의 시험관 내 Amphotericin B 내성 성적어영, 기승정, 김수현, 김의종, 박지영, 서순팔, 신명근, 신종희, 양동욱대한진단검사의학회 · Annals of Laboratory Medicine2008 · 제28권 제5호한국인의 임상분리 아스페르길루스 균주에 대한 보리코나졸의 생체외 감수성조덕, 기승정, 박미라, 박영규, 서순팔, 송정원, 신동현, 신명근, 신종희, 양동욱, 정숙인대한의진균학회 · 대한의진균학회지2004 · 제9권 제3호

이 간행물의 다른 논문 (13건)

Endoscopic Laser Surgery for Subglottic Stenosis in Wegener’s GranulomatosisJacob Shvero, Dekel Shalomi, Rumelia Koren, Mordechai Reuven Kramer, David Shitritpp. 748-753Expression and Regulation of Osteoprotegerin in Adipose Tissue이은직, 김세화, 김똘미, 이유미, Juan-Ji An, 임승길, Dong-He Hanpp. 765-772Macrolide Resistance Trends in β-Hemolytic Streptococci in a Tertiary Korean Hospital조현미, 황규열, 윤갑준, 김효열, 장인호, 권오건, 노송미, 어영pp. 773-778Different Modulation of the Cortical Silent Period by Two Phases of Short Interval Intracortical Inhibition손영호, 신해원, 강석윤pp. 795-801Lacunar Infarction in Type 2 Diabetes Is Associated with an Elevated Intracranial Arterial Pulsatility Index안철우, 이승엽, 이경열, 이기옥, 박종숙pp. 802-806
원문 보기